Brief Summary
The goal of this study is to compare how well sonrotoclax plus obinutuzumab works versus venetoclax plus rituximab in treating adults with relapsed and/or refractory (R/R) chronica long-lasting disease that changes slowly over time lymphocytic leukemia/small lymphocytic lymphomacancers of the lymphatic system (CLL/SLL). The study will also compare how well sonrotoclax plus rituximab works versus venetoclax plus rituxumab in treating adults with R/R CLL/SLL. The safety of these treatments will also be assessed.
Intervention / Treatment
- Drug: Sonrotoclax
- Drug: Obinutuzumab
- Drug: Rituximab
- Drug: Venetoclax
Inclusion Criteria:
- Confirmed diagnosisthe process of identifying a disease based on signs and symptoms, patient history and medical test results of CLL/SLL that meets the International Workshop on Chronic Lymphocytic Leukemia (iwCLL) criteria
- Received one or more prior therapies for CLL/SLL. For each line of therapy, participants must have received at least 2 cycles of the therapy
- Participants with prior BCL2i exposure are eligible if remissiona reduction or absence of symptoms in disease, can be partial or complete duration was ≥3 years with ≥2 years from last BCL2i intake
- Eastern Cooperative Oncologythe study, diagnosis and treatment of cancer Group (ECOG) Performance Status score of 0, 1, or 2
- Adequate organ function